 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Paragon 28, Inc. (NYSE: FNA), announced today they have received an Investigational Device Exemption (IDE) approval from the FDA to commence a feasibility study for configurations of the SMART Total...

Paragon 28, Inc. Receives FDA Approval for IDE Feasibility Study of Its SMART Total Talus System for use in Conjunction with the APEX 3D Total Ankle Replacement System

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch...

Paragon 28 to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Paragon 28, Inc. (NYSE:FNA Free Report) Investment analysts at B. Riley raised their Q3 2023 earnings per share estimates for Paragon 28 in a report issued on Thursday, August 3rd. B. Riley analyst N. Chatterji now anticipates that the company will post earnings of ($0.09) per share for the quarter...

Q3 2023 Earnings Estimate for Paragon 28, Inc. (NYSE:FNA) Issued By B. Riley

Paragon 28, Inc. (FNA) Q2 2023 Earnings Call Transcript

JMP Securities analyst David Turkaly reiterated a Buy rating on Paragon 28 (FNA Research Report) today and set a price target of $30.00. The comp... JMP Securities analyst David Turkaly reiterated a Buy rating on Paragon 28 (FNA  Research Report...

JMP Securities Reaffirms Their Buy Rating on Paragon 28 (FNA)

Preview: Paragon 28's Earnings

Paragon 28, Inc. (NYSE: FNA) (PARAGON), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2023 after market close on Wednesday, August 2, 2023. The companys management will webcast a...

Paragon 28 To Report Second Quarter Financial Results on August 2, 2023

In trading on Wednesday, shares of Paragon 28 Inc (FNA) crossed above their 200 day moving average of 18.20, changing hands as high as 18.39 per share. Paragon 28 Inc shares are currently trading up about 3.6% on the day...

Bullish Two Hundred Day Moving Average Cross - FNA

Paragon 28 (NYSE:FNA  Get Rating) and Beyond Air (NASDAQ:XAIR  Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, ...

Contrasting Paragon 28 (NYSE:FNA) and Beyond Air (NASDAQ:XAIR)

Paragon 28, Inc. (NYSE:FNA  Get Rating) Director Thomas P. Schnettler sold 6,900 shares of the firms stock in a transaction on Wednesday, June 14th. The stock was sold at an average price of $18.54, for a total value of $127,926.00. Following the completion of the transaction, the ...

Insider Selling: Paragon 28, Inc. (NYSE:FNA) Director Sells $127,926.00 in Stock

Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. Its products include bone graft harvest system, bone marrow aspirate kits, and soft tissue fixation system. The company was founded by Albert DaCosta, Frank Bono, Jim Riegler and Lee Rosenthal in 2010 and is headquartered in Englewood, CO.

Watchers	96
52-Wk Low	$11.81
52-Wk High	$21.49

Market Cap	$1.04B
Volume (M)	243,671.00
52-Wk High	$21.49
52-Wk Low	$11.81

FNA Paragon 28 Inc

About

Feed

News

Sentiment

Earnings

Fundamentals